CORRECTION article

Front. Pharmacol., 19 December 2024

Sec. Experimental Pharmacology and Drug Discovery

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1528449

Corrigendum: Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex

  • 1. Cancer Center at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States

  • 2. Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States

  • 3. Lady Davis Institute, SMBD Jewish General Hospital, Gerald Bronfman Department of Oncology and Division of Experimental Medicine, McGill University, Montreal, QC, Canada

  • 4. Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, United States

  • 5. Immunology and Infectious Disease Center at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States

Article metrics

View details

1,6k

Views

641

Downloads

In the published article, there was an error in Figure 4 as published. One of the lanes (referring to eIF4E) was mistakenly replaced with a control lane (third panel from the top in Figure 4A). The corrected Figure 4 and its caption appear below.

FIGURE 4

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

COVID-19, OC43, SARS-CoV-2, coronavirus, eIF4F, translation initiation complex, Vero E6, A549

Citation

Feng Y, Grotegut S, Jovanovic P, Gandin V, Olson SH, Murad R, Beall A, Colayco S, De-Jesus P, Chanda S, English BP, Singer RH, Jackson M, Topisirovic I and Ronai ZA (2024) Corrigendum: Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex. Front. Pharmacol. 15:1528449. doi: 10.3389/fphar.2024.1528449

Received

14 November 2024

Accepted

26 November 2024

Published

19 December 2024

Volume

15 - 2024

Edited and reviewed by

Heike Wulff, University of California, Davis, United States

Updates

Copyright

*Correspondence: Ze’ev A. Ronai,

† Present address: Sumit Chanda, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics